←
Inbar McCarthy MD FACC1,145 posts
Inbar McCarthy MD FACC avatar

Inbar McCarthy MD FACC

@InbarMcCarthy

🫀Associate Program Director @LaheyCardiology | Assistant Professor @UmassChan | via @BidmcCVI @Stanfordmed | momx2, wife👩🏻‍🍼👩🏻‍❤️‍👨🏻

◷ Joined May 2019▧ 49 Photos and videos
Saad Ur Rahman avatar
⟳ Inbar McCarthy MD FACC retweeted
Saad Ur Rahman@SaadUrRahman55·Nov 11

Another wonderful year at #aha2026! Grateful for the opportunity to share our work, reconnect with colleagues, exchange ideas, and learn about the latest advances in cardiovascular medicine. Always inspiring to grow together and contribute to advancing science! @AHAScience @ACCinTouch

Post attachmentPost attachmentPost attachmentPost attachment
Ron Blankstein avatar
⟳ Inbar McCarthy MD FACC retweeted
Ron Blankstein@RonBlankstein·Oct 5

Tremendous @MassGenBrigham cardiology GR talk by super ⭐️ @sarahcud on cardiac amyloidosis ♥️Marked increase in survival with new therapies ♥️Improved diagnostics --> earlier treatment

Post attachmentPost attachmentPost attachmentPost attachment
American Heart News avatar
⟳ Inbar McCarthy MD FACC retweeted
American Heart News@HeartNews·Oct 5

Mass General Brigham women’s heart health leader to receive the 2026 Dr. Nanette K. Wenger Research Goes Red® Award bit.ly/4rK3CHS

C. Michael Gibson MD avatar
⟳ Inbar McCarthy MD FACC retweeted
C. Michael Gibson MD@CMichaelGibson·Sep 4

Breaking and MASSIVE: Lowering Lp(a) with #pelacarsen in patients with elevated Lp(a) and heart disease does NOT improve cardiovascular outcomes in Phase 3 trial globenewswire.com/news-relea…

Pablo Corral MD avatar
⟳ Inbar McCarthy MD FACC retweeted
Pablo Corral MD@drpablocorral·Sep 2

ESC Congress 2026 🇩🇪 | My Top 20 Lipidology Highlights After an intense few days in Munich — including the opportunity to present our own work — here is my personal selection of the 20 lipid studies and concepts that caught my attention at ESC 2026. 1- VESALIUS-CV | Evolocumab — Earlier, sustained LDL-C lowering translated into clinical benefit, with an important mortality signal. 2- STAREE | Atorvastatin — In adults ≥70, MACE ↓ 30%. Age alone should not justify undertreatment. 3- SHASTA-3/4 | Plozasiran — TG ↓ ~80%, with fewer acute pancreatitis events. 4- AMUNDSEN | Evolocumab — Immediate post-MI initiation: LDL-C goal achieved in 82% vs 40%. 5- KYLO-11 | Lp(a) — One siRNA dose: Lp(a) ↓ up to ~97%, sustained almost one year. 6- CTX310 | ANGPTL3 — One-time CRISPR editing: LDL-C and TG ↓ ~50%. 7- VICTORION-CHALLENGE — Inclisiran substantially outperformed bempedoic acid for LDL-C lowering. 8- CORALreef | Enlicitide — Potent oral PCSK9 inhibition across CV risk and Lp(a) strata. 9- Lepodisiran — Profound Lp(a) lowering plus reductions in OxPL-apo(a)/OxPL-apoB. 10- ION775 | APOC3 — One dose provided sustained apoC-III and TG lowering. 11- HRS-5346 — Oral small-molecule Lp(a) lowering: an exciting new approach. 12- BRIDGE — Structured combination therapy after ACS markedly improved LDL-C goal attainment. 13- Rivocibart | ANGPTL3 — A promising approach for HoFH. 14- AAV8 gene therapy | HoFH — Striking early LDL-C reductions with gene replacement. 15- PROSPECT II | Lp(a) — New links between Lp(a), lipid composition and high-risk coronary plaque. 16- Lp(a) variability — Lp(a) may be less “static” than traditionally assumed. 17- Remnants/TGRL — More evidence linking remnant cholesterol with residual ASCVD risk. 18- Lp(a) & plaque vulnerability — Imaging further connected Lp(a) with vulnerable plaque phenotypes. 19- Lp(a) after ACS — Timing and clinical context may influence Lp(a) interpretation. 20- Precision lipidology — LDL-C, apoB, Lp(a), APOC3, ANGPTL3 and remnants are becoming therapeutic targets. My take-home from Munich? For today: treat earlier, lower and for longer. Use combination therapy when needed. For tomorrow: pills → combination therapy → RNA therapeutics → potentially one-time gene editing. Different technologies. Different targets. Same biology: Cumulative exposure to atherogenic lipoproteins drives atherosclerosis. Reduce exposure earlier, prevent disease earlier. @society_eas @escardio

Post attachment
Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 avatar
⟳ Inbar McCarthy MD FACC retweeted
Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦@DrMarthaGulati·Aug 31

#corcal #esccongress #cvprev 🫀5,772 primary prevention pts (52% women) → CAC-guided vs PCE-guided statin therapy ➡️At 4.2 yrs: MACE 2.7% vs 2.7% HR 0.99 (95% CI 0.71–1.38)- no diff ➡️Noninferiority NOT met due to low event rates but CAC recommended fewer statins with better adherence: 62% CAC 🆚23% PCE So, Risk Scores 🆚 #cac? What’s the best choice?

Eric Topol avatar
⟳ Inbar McCarthy MD FACC retweeted
Eric Topol@EricTopol·Aug 31

In a person with unexplained syncope (fainting), does 14-day ECG monitoring help? A randomized trial #esccongress @NEJM It didn't prevent recurrence, the primary endpoint, but surprisingly it was tied to reduced mortality, possibly related to other treatments, such as pacemaker implantation nejm.org/doi/full/10.1056/NE…

Post attachment
Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 avatar
⟳ Inbar McCarthy MD FACC retweeted
Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦@DrMarthaGulati·Aug 31

SHASTA-3/4 #esccongress 🫀757 pts with severe hyperTG (22% women👎🏽) → plozasiran 25 mg q3mo 🆚 placebo At 12 mo: ⤵️TG 79% & 81% (P<.0001) 🆚 placebo ⤵️acute pancreatitis events 78% 90% achieved TG <500 mg/dL on plozasiran ⚡️Powerful TG lowering AND fewer pancreatitis events: New therapy for our patients

Post attachmentPost attachmentPost attachmentPost attachment